Top Markets
#1 Siren Siren +39.12%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#3 Ocean Protocol Ocean Protocol +15.51%
#4 KUB Coin KUB Coin +15.08%
#5 Perle Perle +11.39%
#6 Audiera Audiera +11.03%
#7 Nockchain Nockchain +9.99%
#8 Geodnet Geodnet +9.30%
#9 Arowana Arowana +8.26%
#10 Wiki Cat Wiki Cat +8.24%
Coin of the day
Siren Siren
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Classifica tra le azioni #31934
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Prezzo delle azioni
$0.2619
Ultima sincronizzazione: 2026-08-17
Capitalizzazione di mercato
$11.62M
Variazione (1 giorno)
-2.13%
Variazione (1 anno)
-92.30%
Paese
US
Scambia VistaGen Therapeutics, Inc. (VTGN)

Categoria

Healthcare
Il prezzo VTGN con la capitalizzazione del mercato della B
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
VTGN
$0.2619
Capitalizzazione di mercato di VistaGen Therapeutics, Inc.(VTGN)
Capitalizzazione di mercato: $11.62M
A partire dal August 2026, VistaGen Therapeutics, Inc. ha una capitalizzazione di mercato pari a $11.62M. Questo rende VistaGen Therapeutics, Inc. la 31934th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di VistaGen Therapeutics, Inc. dal 2011 al 2026
VTGN in paragone con la classifica dei più popolari stocks
Il prezzo per VTGN Attivo B Capitalizzazione del mercato a B Risultati
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$123,040 $11.62M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.460T +46,979,716.61%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$101,167 $11.62M
Apple Inc. Apple Inc.
AAPL
$4.489T +38,628,057.12%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$93,311.87 $11.62M
Alphabet Inc. Alphabet Inc.
GOOG
$4.141T +35,628,715.01%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$80,414.22 $11.62M
Microsoft Corporation Microsoft Corporation
MSFT
$3.569T +30,704,070.07%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$63,051.48 $11.62M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.798T +24,074,540.22%